Clopidogrel results in favorable changes in nitric oxide metabolism in patients undergoing percutaneous coronary intervention

Thrombosis and Haemostasis

Volumn 111, Issue 2, 2013, Pages 373-374

  Bundhoo, Shantu ^a   Sagan, Ewelina ^a   James, Philip E ^a   Anderson, Richard A ^a  

^a CARDIFF UNIVERSITY SCHOOL OF MEDICINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; CYCLIC GMP; ENDOTHELIAL NITRIC OXIDE SYNTHASE; NITRIC OXIDE; NITRITE; S NITROSOTHIOL; ANTITHROMBOCYTIC AGENT; BIOLOGICAL MARKER; DRUG DERIVATIVE; NITRIC ACID DERIVATIVE; TICLOPIDINE;

ANTIOXIDANT ACTIVITY; BIOAVAILABILITY; CORONARY ARTERY DISEASE; ENDOTHELIAL DYSFUNCTION; HUMAN; HYPOXIA; ISCHEMIA; LETTER; LOADING DRUG DOSE; METABOLISM; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; THROMBOCYTE AGGREGATION; UPREGULATION; VASODILATATION; BLOOD; DRUG EFFECT; EQUIPMENT; PATHOPHYSIOLOGY; PROSPECTIVE STUDY; STENT; TIME; TREATMENT OUTCOME; UNITED KINGDOM;

BIOLOGICAL MARKERS; CORONARY ARTERY DISEASE; CYCLIC GMP; HUMANS; NITRATES; NITRIC OXIDE; NITRITES; PERCUTANEOUS CORONARY INTERVENTION; PLATELET AGGREGATION INHIBITORS; PROSPECTIVE STUDIES; STENTS; TICLOPIDINE; TIME FACTORS; TREATMENT OUTCOME; VASODILATION; WALES;

EID: 84893176191     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH13-05-0394     Document Type: Letter

References (10)

1. Mehta SR, Yusuf S, Peters RJ, et al. Effects of pre-treatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 2001; 358: 527-533.
2. Warnholtz A, Ostad MA, Velich N, et al. A single loading dose of clopidogrel causes dose-dependent improvement of endothelial dysfunction in patients with stable coronary artery disease: results of a double-blind, randomized study. Atherosclerosis 2008; 196: 689-695.
3. Rudez G, Duckers HJ, Simoons ML. Clopidogrel and endothelial injury after percutaneous coronary interventions: beyond the antiplatelet effects. J Am Coll Cardiol 2010; 56: 1032-1033.
4. Rhodes P, Leone AM, Francis PL, et al. The L-argi-nine:nitric oxide pathway is the major source of plasma nitrite in fasted humans. Biochem Biophys Res Commun 1995; 209: 590-596.
5. Kleinbongard P, Dejam A, Lauer T, et al. Plasma nitrite reflects constitutive nitric oxide synthase activity in mammals. Free Radic Biol Med 2003; 35: 790-796.
6. Pinder AG, Rogers SC, Khalatbari A, et al. The measurement of nitric oxide and its metabolites in biological samples by ozone-based chemilumines-cence. Methods Mol Biol 2009; 476: 10-27.
7. Cao G, Prior RL. Measurement of oxygen radical absorbance capacity in biological samples. Methods Enzymol 1999; 299: 50-62.
8. Ingram TE, Pinder AG, Bailey DM, et al. Low-dose sodium nitrite vasodilates hypoxic human pulmonary vasculature by a means that is not dependent on a simultaneous elevation in plasma nitrite. Am J Physiol 2010; 298: H331-339.
9. Lundberg JO, Weitzberg E. NO generation from nitrite and its role in vascular control. Arterioscler Thromb Vasc Biol 2005; 25: 915-922.
10. Ingram TE, Bleasdale RA, Templeton C, et al. Low-dose sodium nitrite provides targeted relief of myocardial ischaemia in patients with coronary artery disease. Eur Heart J (Suppl 2010); 31: Abstract.